TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
According to the BCLC staging system treatment recommendation, systemic treatment is
recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for
patients in this stage. Studies have shown that TACE combined with sorafenib therapy has
shown effectiveness in the treatment of advanced liver cancer, and PD-1 inhibitors have also
shown effectiveness in the treatment of advanced liver cancer. Therefore, in order to improve
the survival benefit of BCLC stage C liver cancer patients, this clinical study was designed
to evaluate the effectiveness and safety of TACE combined with sorafenib and tislelizumab in
the treatment of BCLC stage C liver cancer patients.